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Sir,
We read the interesting article by Morgan and Davies (2005) on
the novel therapeutic strategies such as thalidomide and deriva-
tives, proteasome inhibitors, and targeted therapy in the main-
tenance setting or in the induction phase of myeloma treatment
prior to high-dose therapy (HDT). They emphasised the im-
portance of the characterisation of the myeloma genome before
selecting a treatment, the diagnosing of myeloma at an early stage
to deliver the novel treatment in the natural history of their
disease, and the establishment of the response rates and lengths
of remission before novel combinations could be compared with
HDT. However, there is no mention about the novel antitumour
activity of bisphosphonates (BPs) besides its inhibiting effects on
bone resorption in multiple myeloma (MM).
As is well known, BPs are used to treat osteoclast-mediated bone
diseases, including osteoporosis, Paget’s disease, hypercalcemia
of malignancy, bone metastases, and bone disease associated with
MM (Berenson et al, 1996; Jantunen, 2002). Current views suggest
that BPs may affect differentiation and recruitment of osteoclast
precursors (Hughes et al, 1989) or alter the capability of mature
osteoclasts to resorb bone by altering the permeability of the
osteoclast membranes to small ions (Sato et al, 1991). As a
member, the more potent nitrogen-containing group of BPs,
zoledronic acid, inhibits protein prenylation, thus affecting
osteoclast function and survival. As protein prenylation is required
by all cells, not just osteoclasts, the possibility that nitrogen-
containing BPs could also affect the viability of tumour cells arises
(Green, 2003). Several studies have clearly demonstrated that BPs
are cytostatic to tumour cells in vitro, induce apoptosis, inhibit cell
adhesion and interfere with the metastatic process (Aparicio et al,
1998). We have recently demonstrated that zoledronic acid
induced antiproliferative and apoptotic effects on MM cell lines
in vitro by activating protein kinase C and increasing extracellular
calcium concentration, and these effects augmented with dexa-
methasone and thalidomide addition to zoledronic acid (Ural et al,
2003). Bisphosphonates may exert their antimyeloma effect by
inhibiting release of bone marrow-derived growth factor, such as
transforming growth factor b and insulin-like growth factor into
marrow, by inducing apoptosis of MM cells, by downregulating
production of interleukin 6 from bone marrow stroma, and by
stimulating gd T-cell-mediated antiplasma cell activity in the
marrow (Mundy and Yoneda, 1998; Kunzmann et al, 2000).
Therefore, zoledronic acid may augment in vivo the therapeutic
action of dexamethasone and thalidomide through direct effects on
myeloma cells as well as by inhibition of paracrine and autocrine
signals by bone marrow stromal cells (Corral et al, 1996; Tassone
et al, 2000). In this context, the results of clinical studies have
suggested that BPs may reduce tumor burden and may improve
survival of patients with MM (Berenson et al, 1998; Mundy and
Yoneda, 1998). In addition, objective remission or inhibition of
disease progression has been reported in patients with MM who
underwent pamidronate treatment alone (Dhodapkar et al, 1998).
In another study of ours, we demonstrated that zoledronic acid
was able to increase disease-free survival in the pristane-induced
plasmacytoma, a model with no direct bone involvement, in BALB/
c mice model (Avcu et al, 2005). In this study, zoledronic acid
treatment markedly impeded intraperitoneal plasmacytoma deve-
lopment. It also decreased tumour burden and extramedullary
tumour growth in mice. Moreover, in contrast to many other
animal tumours studied, which used high doses of BPs (Guenther
et al, 2002; Croucher et al, 2003), the zoledronic acid dose of
20mgkg
1week
1 s.c., which was efficacious in the murine
plasmacytoma model is approximately equivalent to the approved
clinical dose for the treatment of the skeletal complications of MM
(4mg every 3–4 weeks i.v.). All these results raise the possibility
that nitrogen-containing BPs, such as zolederonic acid, with their
direct antitumour effects, may be valuable adjuncts to the novel
therapeutic strategies in the treatment of MM.
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